3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
Dexamethasone
4
XENP 1595
2
Electroencephalography
2
selinexor
1
pomalidomide
1
ixazomib
1
fasudil
1
birtamimab
1
UE2343
1
Telemedicine
1
Tablets
1
Standard of Care
1
Rosiglitazone
1
Propofol
1
Positron-Emission Tomography
1
Methods
1
Melphalan
1
Mass Screening
1
Magnetic Resonance Imaging
1
Lysine Acetyltransferase 5
1
Hypnosis
1
Hormones
1
Exercise
1
Ethanol
1
Donepezil
1
Cyclophosphamide
1
Control Groups
1
Calcium Dobesilate
1
Bortezomib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Alzheimer Disease
×
UE2343
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled